MORI-BUILDING
24.1.2023 03:01:40 CET | Business Wire | Press release
Mori Building Co., Ltd., Japan’s leading urban landscape developer, announced today that the 49-story Toranomon Hills Station Tower will open this coming autumn. This project is being led by the Toranomon 1 & 2-chome District Urban Redevelopment Association, in which Mori Building is a leading participant. With the birth of Toranomon Hills Station Tower, which currently is being thoroughly integrated with Toranomon Hills Station, the entire Toranomon Hills area, which has been expanding and evolving at an unprecedented speed toward the realization of a new international hub and global business center, will be completed as a “city” boasting a scale and impact comparable to that of Roppongi Hills.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230123005232/en/
Completion image of Toranomon Hills (Note: please be sure to state the copyright “©The Boundary” when using this image.) (Graphic: Business Wire)
Toranomon Hills Station Tower is a multi-purpose 266-meter high tower with 49 floors above ground and 4 floors underground. By integrating the overall development with Toranomon Hills Station on the Tokyo Metro Hibiya Line, the tower will be complemented by a large and bustling station plaza and a pedestrian deck measuring 20 meters in width above Sakurada-dori Avenue (National Route 1), offering access to Toranomon Hills Mori Tower Oval Square. By strengthening and expanding the local multilevel transportation network on the ground, underground and the deck-level, the Station Tower will greatly enhance the Toranomon Hills as a transportation node and will enliven the entire area by significantly improving pedestrian flows.
The Station Tower will offer world-class office, as well as retail facilities integrated with the station plaza and a hotel making its debut in Tokyo. The tower‘s top-most level will be home to TOKYO NODE, an interactive communication facility consisting of halls, galleries, pool, restaurants, and other facilities fully capable of creating new values, ideas and business transcending domains, aimed at sharing creativity with the world.
The Toranomon Hills will be expanded to 7.5ha and total floor space of 800,000m2 with the opening of Toranomon Hills Station Tower in autumn, 2023. The area is steadily evolving as a mixed‐use complex integrated with urban infrastructures such as road and subway, with an impact comparable to that of Mori Building's epoch-making Roppongi Hills.
Open and Lively “Station Atrium” Created through Integrated Development of Station and Neighborhood
The Station Atrium (2,000m2) is a three-story atrium-style vaulted space combining coordinated and complementary urban and transportation functions.
The Station Atrium’s direct connections between the station plaza and nearby facilities for events and shopping keep the space bustling with a steady flow of people from morning till night.
20m-wide Large-scale Pedestrian T-Deck above Arterial Road
The 20m-wide large-scale pedestrian T-deck above Sakurada-dori Avenue (National Route 1) and connected to Toranomon Hills Mori Tower’s Oval Square. The elevated walkway, which passes through the Station Tower, is the main route for east-west pedestrian traffic, crossing districts and arterial road. It realizes safe urban spaces by separating pedestrians and vehicles in the area, and will function as a square linking people in Toranomon Hillls.
Interactive Communication Facility Connecting Tokyo with the World: TOKYO NODE
Toranomon Hills Station Tower’s top floors (45th to 49th floors, partly 8th) will be a home to TOKYO NODE, a 10,000m2 interactive communication facility.
Main hall and three galleries can be used individually or integrated as one contiguous venue. On the rooftop, sky garden, pool, and two restaurants curated by world-class chefs will open, including a grill restaurant supervised by Kei Kobayashi, the first Asian chef to earn three Michelin stars in Paris. The laboratory on the 8th floor, will further enhance the facility’s capacity as a highly functional and distinctive space for communication and knowledge-sharing, wholly unlike traditional conference and banquet facilities.
Furthermore, TOKYO NODE will serve as an information dissemination platform of for the entire Toranomon Hills area, allowing Toranomon Hills to evolve into a “communication hub” that attracts highly experienced and influential people from throughout the world for business creation and innovation to share globally.
New Office Space for Connecting People
Responding to Diverse Needs and New Workstyles
Office area located on 9th, 10th, 15-44th floors (total 32 floors), offers a total rental area measuring some 107,000 m2 and standard floors of about 3,400m2, including column-free plans with depths from core to window surface of about 18.5m, accommodate diverse workstyles and other needs of global companies.
In addition, eight "magnet zones" are equipped with atrium spaces and staircases, connecting the upper and lower floors to promote communication and collaboration among workers, and create more dynamic and creative workplaces.
Retail Facilities Support Global Players’ Work and Lives
A retail space measuring about 14,400m2 will occupy nine floors (B2-7th) with some 80 stores that support the work and lives of global players including office workers and residents.
The T‐Market (27 shops, approx. 3,000m2) will be full of life from morning till night (7am to 11pm) with restaurants, delis and stores. The restaurants will offer high-quality but reasonably priced menus, many curated by highly acclaimed chefs and pâtissiers, including some with Michelin or Bib Gourmand credentials.
Hotel Toranomon Hills: Tokyo's First Unbound Collection by Hyatt
The 1st floor and 11th to 14th floors will be home to the Hotel Toranomon Hills with 205 guest rooms including standard rooms measuring about 27m2 to 34m2. The hotel brand is “The Unbound Collection by Hyatt,” which will be making its debut in Tokyo as a part of “Independent Collection.”
It will serve as an “urban living room of Toranomon” welcoming a variety of guests with its restaurant, cafe and lounges open to the city.
All food and beverage experiences in the hotel‘s café and restaurant will be supervised by Sergio Herman,. Herman is a native of the Netherlands and longtime Michelin-starred chef and this will be his first foray into Japan.
World-leading Architects, Designers and Artists
- Design: Shohei Shigematsu (OMA)
The Design of Toranomon Hills Station Tower is OMA’s first large-scale architectural project in Tokyo.
Its design is based on ”THE ACTIVITY BAND” concept, or urban axis running from Shintora-dori Avenue to the Akasaka/Toranomon area, creating a symbolic place for people to gather and interact along the axis.
- Hotel Design (interior): Space Copenhagen
The hotel interior design is by Space Copenhagen, a Denmark Interior design firm, which will be their first interior design in Japan.
Multiple Global Environmental Certifications Received
Toranomon Hills area received preliminary Platinum certification, the highest rank in the LEED program’s ND category.
Station Tower’s offices and retail facilities have received preliminary Platinum certification in the BD+C:CS category and WELL preliminary certification and are expected to earn top Platinum certification once completed. It is Japan’s second largest precertified property, following the Azabudai Hills.
In addition, Station Tower will be 100% powered by RE100-compliant renewable energy from the time of its completion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005232/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
